NetworkNewsBreaks – Vivos Therapeutics Inc. (NAS
Post# of 51
(Total Views: 344)
Posted On: 03/05/2021 3:59:55 PM
NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Establishes Clinical Advisory Board to Help Drive Growth
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), announced the creation of its new Clinical Advisory Board. The six-member board will focus on driving adoption and growth of Vivos’ next-gen treatments for OSA. Reports indicate that an estimated 1 billion people around the world struggle with OSA. Members of Vivos’ new board include the following: neurologist and sleep specialist Clete A. Kushida, MD, PhD; nationally recognized key opinion leader Edward Zuckerberg, DDS; co-founder of the American Academy of Physiological Medicine and Dentistry Michael Gelb, DDS, MS; board-certified sleep specialist and pediatric pulmonologist Manisha Witmans, MD, FAASM; private practitioner in craniofacial sleep medicine and dentistry Tammarie Heit, DDS, MICCMO, RN; and American Sleep and Breathing Academy Diplomate Jon Caulfield, DDS. “In forming Vivos’ new Clinical Advisory Board, we sought out the world’s leading minds in the sleep medicine and dentistry fields,” said Vivos Therapeutics chairman and CEO Kirk Huntsman in the press release. “Each member holds the highest level of credentials and brings decades of combined experience to the table. They are charged with ensuring that our Vivos System technology remains at the forefront of treatment for patients continuing to suffer from sleep apnea across the U.S.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), announced the creation of its new Clinical Advisory Board. The six-member board will focus on driving adoption and growth of Vivos’ next-gen treatments for OSA. Reports indicate that an estimated 1 billion people around the world struggle with OSA. Members of Vivos’ new board include the following: neurologist and sleep specialist Clete A. Kushida, MD, PhD; nationally recognized key opinion leader Edward Zuckerberg, DDS; co-founder of the American Academy of Physiological Medicine and Dentistry Michael Gelb, DDS, MS; board-certified sleep specialist and pediatric pulmonologist Manisha Witmans, MD, FAASM; private practitioner in craniofacial sleep medicine and dentistry Tammarie Heit, DDS, MICCMO, RN; and American Sleep and Breathing Academy Diplomate Jon Caulfield, DDS. “In forming Vivos’ new Clinical Advisory Board, we sought out the world’s leading minds in the sleep medicine and dentistry fields,” said Vivos Therapeutics chairman and CEO Kirk Huntsman in the press release. “Each member holds the highest level of credentials and brings decades of combined experience to the table. They are charged with ensuring that our Vivos System technology remains at the forefront of treatment for patients continuing to suffer from sleep apnea across the U.S.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Vivos Therapeutics Inc. (VVOS) Stock Research Links
Scroll down for more posts ▼